secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRIDEX CORP (IRIX)
CIK:        0001006045
Form:       8-K
Filed at:   2026-08-18T20:51:26+00:00
Accession:  0001193125-26-355635
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iridex Q2 revenue down 7% to $12.6M; glaucoma G6 up 19%, retina weak
--------------------------------------------------------------------

- Total revenue $12.6M, down 7% YoY; net loss $1.3M ($0.07/share) vs $1.0M loss prior year.
- Cyclo G6 family revenue $3.9M (+19% YoY) on 17,700 probes sold (+35% volume); retina revenue $6.5M vs $8.0M.
- Non-GAAP adjusted EBITDA loss $0.4M vs +$21K prior year; operating cash flow positive in Q2.
- Reaffirms FY2026 revenue guidance $51-53M; adjusted opex $19-19.5M; cash $4.7M.
- Retina decline due to Middle East disruptions and China sell-through; expects improvement with Pascal platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006045/000119312526355635/0001193125-26-355635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006045/000119312526355635/irix-20260818.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-355635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer